Investigator |
Title |
Sponsor |
ID |
Dates |
Amount |
David Hooper, MD |
Genomics of Nephrotic Syndrome |
National Institutes of Health (NIH)/Duke University |
265416 / A034556 |
7/27/21-5/31/25 |
$1,000 |
David Hooper, MD |
Preemptive Rituximab to Preven |
Department of Defense/Duke University |
N006814101 |
9/1/20-8/31/22 |
$2,859 |
Donna Claes, MD |
Development of the Pediatric P |
Food and Drug Administration/Children's Hospital of Philadelphia |
GRT-00000431 |
8/1/20-7/31/22 |
$7,999 |
David Hooper, MD |
VIRTUUS Children's Study-Valid |
National Institutes of Health (NIH)/Children's Hospital of Philadelphia |
3200880522 |
6/1/21-5/31/22 |
$11,736 |
Mark M Mitsnefes, MD |
CKID IV (patient care only). |
National Institutes of Health (NIH)/Children's Mercy Hospital |
18-0007 |
8/1/21-7/31/22 |
$16,895 |
Stuart Goldstein, MD |
Clinical Ancillary Study to th |
American Heart Association - National/Stanford University |
62661882-212356 |
7/1/21-6/30/22 |
$26,400 |
Mark M Mitsnefes, MD |
Johns Hopkins CKID Strain Analysis |
National Institutes of Health (NIH)/Johns Hopkins University |
John Hopkins, Mitsne |
6/1/21-7/31/21 |
$28,125 |
Elif Erkan, MD-MS |
CUREGN 2.0 - Midwest Pediatric Nephrology Consorti |
National Institutes of Health (NIH)/Nationwide Children's Hospital |
700198-0620-00 |
6/1/21-5/31/22 |
$30,498 |
Mark M Mitsnefes, MD |
Purchased Services agreement b |
National Institutes of Health (NIH)/Children's Hospital of Philadelphia |
CHOP, Misnefes Mark |
8/1/20-7/31/21 |
$31,250 |
David Hooper, MD |
Advancing Transplantation Outc |
National Institutes of Health (NIH)/Harvard Medical School |
GENFD0002098919 |
9/7/21-6/30/22 |
$41,892 |
Mark M Mitsnefes, MD |
CKID IV (patient care and sala |
National Institutes of Health (NIH)/Children's Mercy Hospital |
18-0007 |
8/1/21-7/31/22 |
$42,430 |
Mark M Mitsnefes, MD |
Preserving Kidney Function in |
Patient-Centered Outcome Research Inst./Children's Hospital of Philadelphia |
GRT-00001109 |
6/1/21-5/31/22 |
$50,679 |
Mark M Mitsnefes, MD |
Phosphate binder therapy and chronic kidney diseas |
National Institutes of Health (NIH)/UCLA School of Public Health |
1652 G YA029 |
5/1/21-4/30/22 |
$52,575 |
Stuart Goldstein, MD |
A multi-center, pilot study to |
University of Michigan |
5500019918- Goldstei |
9/1/20-8/31/22 |
$64,402 |
Ellen Cody, MD |
Systemic Lupus Erythematosus (SLE) |
Lupus Foundation of America |
LFA_Cody |
10/1/21-9/30/22 |
$70,000 |
Elif Erkan, MD-MS |
Urinary Lipidomic profile in F |
National Institutes of Health (NIH) |
1R03TR003916-01A1 |
8/1/21-5/31/22 |
$79,500 |
Meredith Schuh, MD |
KidneyCure Transition to Indep |
American Society of Nephrology |
ASN- Schuh |
7/1/21-6/30/22 |
$100,000 |
Prasad Devarajan, MD |
Research Training in Pediatric Nephrology |
National Institutes of Health (NIH) |
T32DK007695 |
7/1/21-6/30/22 |
$120,492 |
Stuart Goldstein, MD |
Spread of Safety Interventions |
Agcy for Healthcare Research and Quality/Children's Hospital Boston |
RHS027401A |
8/1/21-7/31/22 |
$137,190 |
Prasad Devarajan, MD |
Critical Translational Studies in Pediatric Nephrology |
National Institutes of Health (NIH) |
P50 DK096418 |
9/1/21-8/31/22 |
$850,000 |
Total Annual Grant Award Dollars |
$1,765,922 |